<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660842</url>
  </required_header>
  <id_info>
    <org_study_id>MITO-7</org_study_id>
    <secondary_id>2008-001754-40</secondary_id>
    <nct_id>NCT00660842</nct_id>
  </id_info>
  <brief_title>Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer</brief_title>
  <acronym>MITO-7</acronym>
  <official_title>Weekly Versus Every 3 Week Carboplatin and Paclitaxel in Patients With Ovarian Cancer: a Phase III Randomized Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study efficacy and the effects on quality of life in women
      with ovarian cancer treated with a weekly schedule of chemotherapy with carboplatin and
      paclitaxel compared to those treated with standard every 3 weeks schedule of the same
      chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard first-line treatment of ovarian cancer is combination chemotherapy with
      carboplatin and paclitaxel, given every 3 weeks. Researchers are looking at new ways of
      giving chemotherapy to make it more tolerable and more effective. One way is by giving the
      chemotherapy more often in smaller doses. This approach can be associated with fewer or less
      troubling side effects. Some chemotherapy drugs such as paclitaxel have been shown to also be
      more active when given once a week rather than once every 3 week schedule.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>quality of life</measure>
    <time_frame>weekly for the first 9 weeks of therapy, then every 3 weeks until the completion of therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>every 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>after 9 and 18 weeks of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>weekly during therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>describe the frequency and duration of symptoms in 12 months preceding ovarian cancer diagnosis</measure>
    <time_frame>at study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>describe time intervals of prediagnostic sentinel events (onset of persistent symptoms, first physician visit, diagnosis of ovarian cancer)</measure>
    <time_frame>at study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>describe patients' pathway to diagnosis of ovarian cancer according to modified Andersen's model of 'total patient delay'</measure>
    <time_frame>at study entry</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>weekly chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>every 3 weeks chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>AUC 6 IV day 1 every 21 days</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>175 mg/m2 IV day 1 every 21 days</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>AUC 2 IV every week</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>60mg/m2 IV every week</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytologic or histologic diagnosis of ovarian carcinoma of the ovary, fallopian tube or
             primary peritoneal carcinoma, stage IC-IV

          -  Indication for chemotherapy

          -  Age &gt; 18 years

          -  Life expectancy of at least 3 months

        Exclusion Criteria:

          -  Previous or concomitant malignant malignancy (excluding adequately treated baso-or
             squamocellular carcinoma of the skin and carcinoma in situ of the cervix, and
             synchronous endometrioid carcinoma Stage Ib or less for the uterus, with ovarian tumor
             Stage II or higher)

          -  Performance Status (ECOG) &gt; or = 3.

          -  Previous chemotherapy

          -  Heart disease (congestive heart failure, myocardial infarction within 6 months from
             study entry, atrioventricular block of any grade, severe arrhythmias)

          -  Neutrophils &lt; 2000 x mm3, platelets &lt; 100000 x mm3

          -  Inadequate renal function (creatinine &gt; or = 1.25 x normal values) or liver function
             (ALT or AST &gt; or = 1.25 x normal values)

          -  Present or suspected hemorrhagic syndromes

          -  Inability to comply with protocol and follow-up

          -  Inability to access study site for clinical visits

          -  Refusal of informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandro Pignata, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marilina Piccirillo, M.D.,</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ciro Gallo, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Oncologico Bari, Oncologia Medica</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Riuniti di Bergamo, U.O. di Ostetricia e Ginecologia</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Fatebenefratelli, U.O. di Oncologia</name>
      <address>
        <city>Benevento</city>
        <state>BN</state>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera G. Rummo</name>
      <address>
        <city>Benevento</city>
        <state>BN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore, Dipartimento di Oncologia</name>
      <address>
        <city>Campobasso</city>
        <state>CB</state>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera C. Poma</name>
      <address>
        <city>Mantova</city>
        <state>MN</state>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera V. Cervello</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Massimo, Day Hospital Oncologico</name>
      <address>
        <city>Penne</city>
        <state>PE</state>
        <zip>65017</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico, Divisione di Oncolgia Medica C</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Chiara</name>
      <address>
        <city>Trento</city>
        <state>TN</state>
        <zip>38100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Bortolo ULSS 6, U.O. di Oncologia Medica</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mazzoni</name>
      <address>
        <city>Ascoli Piceno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Bari Policinico I Clinical Ostetrica e Ginecologica</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Fatebenefratelli</name>
      <address>
        <city>Benevento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Senatore Antonio Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Cattolica del Sacro Cuore</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale A. Manzoni</name>
      <address>
        <city>Lecco</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Univeristaria Policlinico</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera D. Cotugno</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori , Oncologia Medica - Dipartimento Uro-Ginecologico</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Federico II, Cattedra di Oncologia Medica</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Silvestrini</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile S. Spirito</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. S. Maria degli Angeli</name>
      <address>
        <city>Pordenone</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giovanni Calibita Fatebenefratelli, UO di Oncologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. di Udine S. Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014 Apr;15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X. Epub 2014 Feb 28.</citation>
    <PMID>24582486</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2008</study_first_submitted>
  <study_first_submitted_qc>April 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>quality of life</keyword>
  <keyword>weekly therapy</keyword>
  <keyword>neurotoxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

